Franois Bertucci

List of Publications by Year in Descending Order

113 papers	3,183 citations	32 h-index	54 g-index
131 ext. papers	4,262 ext. citations	7.8 avg, IF	5.18 L-index

#	Paper	IF	Citations
113	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. *Npj Breast Cancer*, **2022**, 8, 12	7.8	0
112	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. *Cell Death and Disease*, **2022**, 13, 96	9.8	1
111	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.. *Cell Research*, **2022**,	24.7	7
110	Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. *Cancer Research*, **2022**, 82, P1-04-07-P1-04-07	10.1	
109	Ketogenic HMG-CoA lyase and its product hydroxybutyrate promote pancreatic cancer progression.. *EMBO Journal*, **2022**, e110466	13	2
108	Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease.. *Current Oncology*, **2022**, 29, 1683-1694	2.8	1
107	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. *Journal of Personalized Medicine*, **2022**, 12, 655	3.6	0
106	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.. *Science China Life Sciences*, **2022**, 1	8.5	1
105	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks Outcome?. *Cancers*, **2022**, 14, 2620	6.6	0
104	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. *European Journal of Cancer*, **2021**, 159, 205-214	7.5	0
103	Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. *Frontiers in Oncology*, **2021**, 11, 646992	5.3	1
102	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. *Journal of Investigative Dermatology*, **2021**, 141, 761-769.e2	4.3	3
101	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. *Genome Medicine*, **2021**, 13, 87	14.4	8
100	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. *Journal of Clinical Oncology*, **2021**, 39, 11507-11507	2.2	4
99	Determinants of the access to remote specialised services provided by national sarcoma reference centres. *BMC Cancer*, **2021**, 21, 631	4.8	3
98	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. *Npj Breast Cancer*, **2021**, 7, 48	7.8	0
97	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcS pembrolizumab study from Unicancer.. *Journal of Clinical Oncology*, **2021**, 39, 11520-11520	2.2	0

96	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. *Cancers*, **2021**, 13,	6.6	4
95	Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment. *Biomedicines*, **2021**, 9,	4.8	1
94	WEE1 Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer. *Advanced Science*, **2021**, 8, e2101030	13.6	3
93	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. *Cell Metabolism*, **2021**, 33, 51-64.e9	24.6	57
92	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. *Journal of Clinical Investigation*, **2021**, 131,	15.9	3
91	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. *Clinical Cancer Research* , **2021**, 27, 2314-2325	12.9	3
90	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. *Molecular Oncology*, **2021**, 15, 2752-2765	7.9	3
89	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. *OncoImmunology*, **2021**, 10, 1929724	7.2	4
88	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. *BMC Cancer*, **2020**, 20, 430	4.8	3
87	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response **2020**, 8,		23
86	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. *Cancers*, **2020**, 12,	6.6	15
85	New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi. *Cancers*, **2020**, 12,	6.6	15
84	The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype. *Npj Breast Cancer*, **2020**, 6, 8	7.8	14
83	Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations. *Oncoscience*, **2020**, 7, 57-59	0.8	
82	Inflammatory breast cancer cells are characterized by abrogated TGF1-dependent cell motility and SMAD3 activity. *Breast Cancer Research and Treatment*, **2020**, 180, 385-395	4.4	11
81	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. *In Vivo*, **2020**, 34, 177-184	2.3	6
80	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. *Molecular Oncology*, **2020**, 14, 504-519	7.9	13
79	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. *Current Opinion in Oncology*, **2020**, 32, 585-593	4.2	3

78	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. *Clinical Cancer Research*, **2020**, 26, 5539	12.9	
77	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. *Frontiers in Oncology*, **2020**, 10, 575978	5.3	2
76	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. *Cancers*, **2020**, 12,	6.6	5
75	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 6254-6265	12.9	10
74	Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour. *Case Reports in Oncology*, **2019**, 12, 644-649	1	
73	expression is associated with longer postoperative, survival in adrenocortical carcinoma. *OncoImmunology*, **2019**, 8, e1655362	7.2	16
72	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. *Cancers*, **2019**, 11,	6.6	12
71	PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. *Molecular Oncology*, **2019**, 13, 1577-1588	7.9	14
70	Genomic characterization of metastatic breast cancers. *Nature*, **2019**, 569, 560-564	50.4	256
69	Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. *Journal of Clinical Medicine*, **2019**, 8,	5.1	9
68	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. *Journal of Clinical Medicine*, **2019**, 8,	5.1	2
67	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. *Cancers*, **2019**, 11,	6.6	17
66	Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. *Cancers*, **2019**, 11,	6.6	35
65	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. *British Journal of Cancer*, **2019**, 120, 931-940	8.7	7
64	Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin. *Cancers*, **2019**, 11,	6.6	5
63	Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls". *Cancers*, **2019**, 11,	6.6	14
62	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. *Cancers*, **2019**, 11,	6.6	1
61	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. *Cancers*, **2019**, 11,	6.6	99

60	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. *Clinical Epigenetics*, **2019**, 11, 141	7.7	4
59	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. *EMBO Molecular Medicine*, **2019**, 11, e9930	12	12
58	Sensitive and easy screening for circulating tumor cells by flow cytometry. *JCI Insight*, **2019**, 5,	9.9	16
57	MARCKS protein overexpression is associated with poor prognosis in male breast cancer. *Cancer Biomarkers*, **2019**, 26, 513-522	3.8	4
56	"Wnt/β-Catenin in GIST"-Letter. *Molecular Cancer Therapeutics*, **2018**, 17, 327-328	6.1	4
55	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. *European Journal of Cancer*, **2018**, 99, 28-36	7.5	9
54	Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. *Clinical Sarcoma Research*, **2018**, 8, 11	2.5	1
53	Targeting Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. *Cancers*, **2018**, 10,	6.6	29
52	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. *British Journal of Cancer*, **2018**, 119, 1383-1391	8.7	23
51	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling. *Stem Cell Reports*, **2018**, 11, 1040-1050	8	8
50	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. *OncoImmunology*, **2017**, 6, e1278100	7.2	54
49	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. *Cell Reports*, **2017**, 18, 2256-2268	10.6	81
48	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. *OncoImmunology*, **2017**, 6, e1253654	7.2	87
47	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. *Nature Medicine*, **2017**, 23, 568-578	50.5	78
46	Prognostic Value of Molecular Subtypes in Pancreatic Cancer. *Pancreas*, **2017**, 46, e29-e31	2.6	7
45	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. *Expert Review of Anticancer Therapy*, **2017**, 17, 593-606	3.5	1
44	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). *Neoplasia*, **2017**, 19, 564-573	6.4	15
43	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. *European Journal of Cancer*, **2017**, 86, 28-36	7.5	35

42	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Letter. *Molecular Cancer Therapeutics*, **2017**, 16, 2324	6.1	2
41	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. *BMC Medicine*, **2017**, 15, 170	11.4	41
40	Validation and comparison of the molecular classifications of pancreatic carcinomas. *Molecular Cancer*, **2017**, 16, 168	42.1	21
39	Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review. *Case Reports in Oncology*, **2017**, 10, 66-76	1	5
38	Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. *International Journal of Molecular Sciences*, **2017**, 19,	6.3	5
37	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. *Current Oncology Reports*, **2017**, 19, 64	6.3	71
36	SPAG5: the ultimate marker of proliferation in early breast cancer?. *Lancet Oncology, The*, **2016**, 17, 863-865	21.7	9
35	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 600-11	21.7	35
34	The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. *OncoImmunology*, **2016**, 5, e1085148	7.2	33
33	Comparative genomic analysis of primary tumors and metastases in breast cancer. *Oncotarget*, **2016**, 7, 27208-19	3.3	53
32	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. *European Journal of Cancer*, **2016**, 58, 90-6	7.5	72
31	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. *Developmental Cell*, **2016**, 37, 311-325	10.2	32
30	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. *Anticancer Research*, **2016**, 36, 293-9	2.3	7
29	Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. *Cancer Genomics and Proteomics*, **2016**, 13, 191-200	3.3	3
28	Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. *Molecular Oncology*, **2015**, 9, 1218-33	7.9	30
27	The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy. *Breast Cancer Research*, **2015**, 17, 54	8.3	2
26	PDL1 expression is an independent prognostic factor in localized GIST. *OncoImmunology*, **2015**, 4, e1002729	7.2	51
25	Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. *Journal of Translational Medicine*, **2015**, 13, 138	8.5	32

24	High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature. *Clinical Sarcoma Research*, **2015**, 5, 25	2.5	2
23	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. *Oncotarget*, **2015**, 6, 13506-19	3.3	87
22	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. *European Journal of Cancer*, **2015**, 51, 742-50	7.5	70
21	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. *Cancer Letters*, **2014**, 355, 70-5	9.9	30
20	ESPL1 is a candidate oncogene of luminal B breast cancers. *Breast Cancer Research and Treatment*, **2014**, 147, 51-9	4.4	31
19	Genomic profiling of inflammatory breast cancer: a review. *Breast*, **2014**, 23, 538-45	3.6	40
18	Personalized medicine: present and future of breast cancer management. *Critical Reviews in Oncology/Hematology*, **2014**, 91, 223-33	7	40
17	Primary synovial sarcoma of the thyroid gland: case report and review of the literature. *Case Reports in Oncology*, **2014**, 7, 6-13	1	16
16	Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. *PLoS ONE*, **2014**, 9, e104302	3.7	35
15	Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. *PLoS ONE*, **2014**, 9, e81843	3.7	42
14	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. *Molecular Cancer*, **2014**, 13, 228	42.1	73
13	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. *Breast Cancer Research*, **2013**, 15, R112	8.3	39
12	Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. *Scandinavian Journal of Gastroenterology*, **2013**, 48, 4-8	2.4	20
11	Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization. *Genes Chromosomes and Cancer*, **2013**, 52, 156-64	5	6
10	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. *Clinical Cancer Research*, **2013**, 19, 4685-96	12.9	99
9	Genomic and expression analysis of microdissected inflammatory breast cancer. *Breast Cancer Research and Treatment*, **2013**, 138, 761-72	4.4	41
8	Difference in therapeutic response between basal and nonbasal triple-negative breast cancers. *Oncologist*, **2013**, 18, 1060-1	5.7	2
7	Gene expression profiling of solitary fibrous tumors. *PLoS ONE*, **2013**, 8, e64497	3.7	13

6	8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. *PLoS ONE*, **2012**, 7, e37943	3.7	27
5	High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. *PLoS ONE*, **2011**, 6, e16950	3.7	50
4	Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. *PLoS ONE*, **2011**, 6, e27656	3.7	108
3	Defining the molecular biology of inflammatory breast cancer. *Seminars in Oncology*, **2008**, 35, 41-50	5.5	47
2	How basal are triple-negative breast cancers?. *International Journal of Cancer*, **2008**, 123, 236-40	7.5	336
1	Integrated profiling of basal and luminal breast cancers. *Cancer Research*, **2007**, 67, 11565-75	10.1	232